1887

Chapter 16 : Mycobacteria

Authors: Patricia J. Simner1, Gail L. Woods2, Nancy L. Wengenack3
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: Division of Medical Microbiology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287; 2: Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205; 3: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905
Content Type: Monograph
Publication Year: 2016

Category: Clinical Microbiology

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Mycobacteria, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819040/9781555819033_Chap16-1.gif /docserver/preview/fulltext/10.1128/9781555819040/9781555819033_Chap16-2.gif

Abstract:

Many species are capable of causing infections in the immunocompromised individual, but and are among the most recognized pathogens in this genus. In broad terms, the mycobacteria are divided into the complex (MTBC) and the nontuberculous mycobacteria (NTM). has long been recognized as a significant human pathogen, and much effort has been applied to the development of diagnostics for the detection of this organism. Historically, the NTMs garnered much less attention than MTBC, but they are now recognized to be important causes of human disease, especially in the immunocompromised host.

Citation: Simner P, Woods G, Wengenack N. 2016. Mycobacteria, p 367-389. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0016-2015
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Mycobacteria
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819040.chap16-1,webId=/content/author/10.1128/9781555819040.chap16-1,properties={foaf_givenname=Patricia J., foaf_name=Patricia J. Simner, foaf_surname=Simner, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819040.chap16-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819040.chap16-2,webId=/content/author/10.1128/9781555819040.chap16-2,properties={foaf_givenname=Gail L., foaf_name=Gail L. Woods, foaf_surname=Woods, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819040.chap16-aff2]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819040.chap16-3,webId=/content/author/10.1128/9781555819040.chap16-3,properties={foaf_givenname=Nancy L., foaf_name=Nancy L. Wengenack, foaf_surname=Wengenack, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819040.chap16-aff3]]}]]
Citation: Simner P, Woods G, Wengenack N. 2016. Mycobacteria, p 367-389. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0016-2015
/content/10.1128/9781555819040.chap16.fig16-1
Figure 1

Algorithm for acid-fast bacteria (AFB) testing.

10.1128/9781555819040/fig16-1_thmb.gif
10.1128/9781555819040/fig16-1.gif
Image of Figure 1
Figure 1

Algorithm for acid-fast bacteria (AFB) testing.

Citation: Simner P, Woods G, Wengenack N. 2016. Mycobacteria, p 367-389. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0016-2015
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819040.chap16
1. Sepkowitz KA,, Raffalli J,, Riley L,, Kiehn TE,, Armstrong D . 1995. Tuberculosis in the AIDS era. Clin Microbiol Rev 8 : 180–199.[PubMed]
2. Halse TA,, Escuyer VE,, Musser KA . 2011. Evaluation of a single-tube multiplex real-time PCR for differentiation of members of the Mycobacterium tuberculosis complex in clinical specimens. J Clin Microbiol 49 : 2562–2567.[PubMed] [CrossRef]
3. Falkinham JO III . 1996. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 9 : 177–215.[PubMed]
4. Runyon EH . 1970. Identification of mycobacterial pathogens utilizing colony characteristics. Am J Clin Pathol 54 : 578–586.[PubMed] [CrossRef]
5. Saubolle MA,, Kiehn TE,, White MH,, Rudinsky MF,, Armstrong D . 1996. Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev 9 : 435–447.[PubMed]
6. Fournier S,, Pialoux G,, Vincent V . 1998. Mycobacterium genavense and cutaneous disease in AIDS. Ann Intern Med 128 : 409. [PubMed] [CrossRef]
7. Petrini B . 2006. Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections. Eur J Clin Microbiol Infect Dis 25 : 609–613.[PubMed] [CrossRef]
8. Lewis FM,, Marsh BJ,, von Reyn CF . 2003. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis 37 : 390–397.[PubMed] [CrossRef]
9. Tebruegge M,, Curtis N . 2011. Mycobacterium marinum infection. Adv Exp Med Biol 719 : 201–210.[PubMed] [CrossRef]
10. Runyon EH . 1965. Typical mycobacteria: their classification. Am Rev Respir Dis 91 : 288–289.[PubMed]
11. Brown-Elliott BA,, Wallace RJ Jr . 2002. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 15 : 716–746.[PubMed] [CrossRef]
12. Adekambi T . 2009. Mycobacterium mucogenicum group infections: a review. Clin Microbiol Infect 15 : 911–918.[PubMed] [CrossRef]
13. Daley CL,, Griffith DE . 2002. Pulmonary disease caused by rapidly growing mycobacteria. Clin Chest Med 23 : 623–632. vii.[PubMed] [CrossRef]
14. Griffith DE,, Girard WM,, Wallace RJ Jr . 1993. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 147 : 1271–1278.[PubMed] [CrossRef]
15. Fangous MS,, Mougari F,, Gouriou S,, Calvez E,, Raskine L,, Cambau E,, Payan C,, Hery-Arnaud G . 2014. Classification algorithm for subspecies identification within the Mycobacterium abscessus species, based on matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 52 : 3362–3369.[PubMed] [CrossRef]
16. Tseng SP,, Teng SH,, Lee PS,, Wang CF,, Yu JS,, Lu PL . 2013. Rapid identification of M. abscessus and M. massiliense by MALDI-TOF mass spectrometry with a comparison to sequencing methods and antimicrobial susceptibility patterns. Future Microbiol 8 : 1381–1389.[PubMed] [CrossRef]
17. Ichihara A,, Jinnin M,, Fukushima S,, Inoue Y,, Ihn H . 2014. Case of disseminated cutaneous Mycobacterium chelonae infection mimicking cutaneous vasculitis. J Dermatol 41 : 414–417.[PubMed] [CrossRef]
18. Arnold C,, Barrett A,, Cross L,, Magee JG . 2012. The use of rpoB sequence analysis in the differentiation of Mycobacterium abscessus and Mycobacterium chelonae: a critical judgement in cystic fibrosis? Clin Microbiol Infect 18 : E131–E133.[PubMed] [CrossRef]
19. Chen JH,, Yam WC,, Ngan AH,, Fung AM,, Woo WL,, Yan MK,, Choi GK,, Ho PL,, Cheng VC,, Yuen KY . 2013. Advantages of using matrix-assisted laser desorption ionization-time of flight mass spectrometry as a rapid diagnostic tool for identification of yeasts and mycobacteria in the clinical microbiological laboratory. J Clin Microbiol 51 : 3981–3987.[PubMed] [CrossRef]
20. Griffith DE,, Brown-Elliott BA,, Wallace RJ Jr . 2015. Hit the road, MAC, and don’t you come back no more. Am J Respir Crit Care Med 191 : 1222–1224.[PubMed] [CrossRef]
21. Boyle DP,, Zembower TR,, Reddy S,, Qi C . 2015. Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am J Respir Crit Care Med 191 : 1310–1317.[PubMed] [CrossRef]
22. Schneider E,, Moore M,, Castro KG . 2005. Epidemiology of tuberculosis in the United States. Clin Chest Med 26 : 183–195.[PubMed] [CrossRef]
23. Thwaites GE,, Lan NT,, Dung NH,, Quy HT,, Oanh DT,, Thoa NT,, Hien NQ,, Thuc NT,, Hai NN,, Bang ND,, Lan NN,, Duc NH,, Tuan VN,, Hiep CH,, Chau TT,, Mai PP,, Dung NT,, Stepniewska K,, White NJ,, Hien TT,, Farrar JJ . 2005. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 192 : 79–88.[PubMed] [CrossRef]
24. Bashar M,, Alcabes P,, Rom WN,, Condos R . 2001. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 120 : 1514–1519.[PubMed] [CrossRef]
25. Bloch KC,, Zwerling L,, Pletcher MJ,, Hahn JA,, Gerberding JL,, Ostroff SM,, Vugia DJ,, Reingold AL . 1998. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 129 : 698–704.[PubMed] [CrossRef]
26. Brown-Elliot BA,, Wallace RJJ, . 2005. Infections caused by nontuberculous mycobacteria, p 2909–2916. In Mandell GL,, Douglass RGJ,, Bennett JE (ed), Principles and Practice of Infectious Diseases, 6th ed. Elsevier Churchill Livingstone, Philadelphia, PA.
27. Corbett EL,, Churchyard GJ,, Hay M,, Herselman P,, Clayton T,, Williams B,, Hayes R,, Mulder D,, De Cock KM . 1999. The impact of HIV infection on Mycobacterium kansasii disease in South African gold miners. Am J Respir Crit Care Med 160 : 10–14.[PubMed] [CrossRef]
28. Field SK,, Cowie RL . 2006. Lung disease due to the more common nontuberculous mycobacteria. Chest 129 : 1653–1672.[PubMed] [CrossRef]
29. Gordin FM,, Horsburgh RC, . 2005. Mycobacterium avium complex, p 2897–2909. In Mandell RGDGL,, Bennett JE (ed), Principles and Practice of Infectious Disease, 6th ed. Elsevier Churchill Livingstone, Philadelphia, PA.
30. Juffermans NP,, Verbon A,, Danner SA,, Kuijper EJ,, Speelman P . 1998. Mycobacterium xenopi in HIV-infected patients: an emerging pathogen. AIDS 12 : 1661–1666.[PubMed] [CrossRef]
31. Benator DA,, Gordin FM . 1996. Nontuberculous mycobacteria in patients with human immunodeficiency virus infection. Semin Respir Infect 11 : 285–300.[PubMed]
32. Karakousis PC,, Moore RD,, Chaisson RE . 2004. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis 4 : 557–565.[PubMed] [CrossRef]
33. Miguez-Burbano MJ,, Flores M,, Ashkin D,, Rodriguez A,, Granada AM,, Quintero N,, Pitchenik A . 2006. Non-tuberculous mycobacteria disease as a cause of hospitalization in HIV-infected subjects. Int J Infect Dis 10 : 47–55.[PubMed] [CrossRef]
34. Phillips P,, Bonner S,, Gataric N,, Bai T,, Wilcox P,, Hogg R,, O’Shaughnessy M,, Montaner J . 2005. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 41 : 1483–1497.[PubMed] [CrossRef]
35. Munoz P,, Rodriguez C,, Bouza E . 2005. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 40 : 581–587.[PubMed] [CrossRef]
36. Singh N,, Paterson DL . 1998. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 27 : 1266–1277.[PubMed] [CrossRef]
37. Torre-Cisneros J,, Doblas A,, Aguado JM,, San Juan R,, Blanes M,, Montejo M,, Cervera C,, Len O,, Carratala J,, Cisneros JM,, Bou G,, Munoz P,, Ramos A,, Gurgui M,, Borrell N,, Fortun J,, Moreno A,, Gavalda J . 2009. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 48 : 1657–1665.[PubMed] [CrossRef]
38. Piersimoni C,, Scarparo C . 2009. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis 15 : 1351–1358, quiz 1544.[PubMed] [CrossRef]
39. Al-Anazi KA,, Al-Jasser AM,, Alsaleh K . 2014. Infections caused by Mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation. Front Oncol 4 : 231. [PubMed] [CrossRef]
40. Russo RL,, Dulley FL,, Suganuma L,, Franca IL,, Yasuda MA,, Costa SF . 2010. Tuberculosis in hematopoietic stem cell transplant patients: case report and review of the literature. Int J Infect Dis 14(Suppl 3): e187–e191.[PubMed] [CrossRef]
41. Doucette K,, Fishman JA . 2004. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 38 : 1428–1439.[PubMed] [CrossRef]
42. Cooksey RC,, Jhung MA,, Yakrus MA,, Butler WR,, Adekambi T,, Morlock GP,, Williams M,, Shams AM,, Jensen BJ,, Morey RE,, Charles N,, Toney SR,, Jost KC Jr,, Dunbar DF,, Bennett V,, Kuan M,, Srinivasan A . 2008. Multiphasic approach reveals genetic diversity of environmental and patient isolates of Mycobacterium mucogenicum and Mycobacterium phocaicum associated with an outbreak of bacteremias at a Texas hospital. Appl Environ Microbiol 74 : 2480–2487.[PubMed] [CrossRef]
43. Livni G,, Yaniv I,, Samra Z,, Kaufman L,, Solter E,, Ashkenazi S,, Levy I . 2008. Outbreak of Mycobacterium mucogenicum bacteraemia due to contaminated water supply in a paediatric haematology-oncology department. J Hosp Infect 70 : 253–258.[PubMed] [CrossRef]
44. Baird SF,, Taori SK,, Dave J,, Willocks LJ,, Roddie H,, Hanson M . 2011. Cluster of non-tuberculous mycobacteraemia associated with water supply in a haemato-oncology unit. J Hosp Infect 79 : 339–343.[PubMed] [CrossRef]
45. Koya MP,, Simon MA,, Soloway MS . 2006. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 175 : 2004–2010.[PubMed] [CrossRef]
46. Lamm DL,, van der Meijden PM,, Morales A,, Brosman SA,, Catalona WJ,, Herr HW,, Soloway MS,, Steg A,, Debruyne FM . 1992. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147 : 596–600.[PubMed]
47. Perez-Jacoiste Asin MA,, Fernandez-Ruiz M,, Lopez-Medrano F,, Lumbreras C,, Tejido A,, San Juan R,, Arrebola-Pajares A,, Lizasoain M,, Prieto S,, Aguado JM . 2014. Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) 93 : 236–254.[PubMed] [CrossRef]
48. Askling J,, Fored CM,, Brandt L,, Baecklund E,, Bertilsson L,, Coster L,, Geborek P,, Jacobsson LT,, Lindblad S,, Lysholm J,, Rantapaa-Dahlqvist S,, Saxne T,, Romanus V,, Klareskog L,, Feltelius N . 2005. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 : 1986–1992.[PubMed] [CrossRef]
49. Brassard P,, Kezouh A,, Suissa S . 2006. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43 : 717–722.[PubMed] [CrossRef]
50. Doucet-Populaire F,, Lalande V,, Carpentier E,, Bourgoin A,, Dailloux M,, Bollet C,, Vachee A,, Moinard D,, Texier-Maugein J,, Carbonnelle B,, Grosset J . 1996. A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group. Tuber Lung Dis 77 : 358–362.[CrossRef]
51. Gomez-Reino JJ,, Carmona L,, Valverde VR,, Mola EM,, Montero MD . 2003. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 : 2122–2127.[PubMed] [CrossRef]
52. Keane J,, Gershon S,, Wise RP,, Mirabile-Levens E,, Kasznica J,, Schwieterman WD,, Siegel JN,, Braun MM . 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 : 1098–1104.[PubMed] [CrossRef]
53. Maini R,, St Clair EW,, Breedveld F,, Furst D,, Kalden J,, Weisman M,, Smolen J,, Emery P,, Harriman G,, Feldmann M,, Lipsky P . 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 : 1932–1939.[CrossRef]
54. Kim HC,, Jo KW,, Jung YJ,, Yoo B,, Lee CK,, Kim YG,, Yang SK,, Byeon JS,, Kim KJ,, Ye BD,, Shim TS . 2014. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay. Scand J Infect Dis 46 : 763–769.[PubMed] [CrossRef]
55. Pablos-Mendez A,, Blustein J,, Knirsch CA . 1997. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 87 : 574–579.[PubMed] [CrossRef]
56. Perez-Guzman C,, Torres-Cruz A,, Villarreal-Velarde H,, Salazar-Lezama MA,, Vargas MH . 2001. Atypical radiological images of pulmonary tuberculosis in 192 diabetic patients: a comparative study. Int J Tuberc Lung Dis 5 : 455–461.[PubMed]
57. Ponce-De-Leon A,, Garcia-Garcia Md,, Mde L,, Garcia-Sancho MC,, Gomez-Perez FJ,, Valdespino-Gomez JL,, Olaiz-Fernandez G,, Rojas R,, Ferreyra-Reyes L,, Cano-Arellano B,, Bobadilla M,, Small PM,, Sifuentes-Osornio J . 2004. Tuberculosis and diabetes in southern Mexico. Diabetes Care 27 : 1584–1590.[PubMed] [CrossRef]
58. Singla R,, Khan N,, Al-Sharif N,, Ai-Sayegh MO,, Shaikh MA,, Osman MM . 2006. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis 10 : 74–79.[PubMed]
59. Jeon CY,, Murray MB . 2008. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 5 : e152. [PubMed] [CrossRef]
60. Bouza E,, Moya JG,, Munoz P . 2001. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 15 : 335–361.[PubMed] [CrossRef]
61. Carmona L,, Hernandez-Garcia C,, Vadillo C,, Pato E,, Balsa A,, Gonzalez-Alvaro I,, Belmonte MA,, Tena X,, Sanmarti R . 2003. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30 : 1436–1439.[PubMed]
62. Ludvigsson JF,, Wahlstrom J,, Grunewald J,, Ekbom A,, Montgomery SM . 2007. Coeliac disease and risk of tuberculosis: a population based cohort study. Thorax 62 : 23–28.[PubMed] [CrossRef]
63. Centers for Disease Control and Prevention (CDC) . 2000. Update: nucleic acid amplification tests for tuberculosis. MMWR Morb Mortal Wkly Rep 49 : 593–594.[PubMed]
64. Herrera V,, Perry S,, Parsonnet J,, Banaei N . 2011. Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis 52 : 1031–1037.[PubMed] [CrossRef]
65. Richeldi L,, Losi M,, D’Amico R,, Luppi M,, Ferrari A,, Mussini C,, Codeluppi M,, Cocchi S,, Prati F,, Paci V,, Meacci M,, Meccugni B,, Rumpianesi F,, Roversi P,, Cerri S,, Luppi F,, Ferrara G,, Latorre I,, Gerunda GE,, Torelli G,, Esposito R,, Fabbri LM . 2009. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 136 : 198–204.[PubMed] [CrossRef]
66. Mazurek GH,, Jereb J,, Vernon A,, LoBue P,, Goldberg S,, Castro K . 2010. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection— United States, 2010. MMWR Recomm Rep 59 : 1–25.[PubMed]
67. Santin M,, Munoz L . 2013. T-cell-based IFN-gamma release assays for the diagnosis of latent tuberculosis infection: have they met our expectations? Expert Rev Mol Diagn 13 : 515–517.[PubMed] [CrossRef]
68. Cattamanchi A,, Smith R,, Steingart KR,, Metcalfe JZ,, Date A,, Coleman C,, Marston BJ,, Huang L,, Hopewell PC,, Pai M . 2011. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 56 : 230–238.[PubMed] [CrossRef]
69. Feng JY,, Huang SF,, Lee MC,, Ting WY,, Chen YC,, Lin YY,, Lee YC,, Su WJ . 2013. Characteristics of IFN-gamma responses in IGRA among pulmonary TB suspects in a TB-endemic area. Diagn Microbiol Infect Dis 77 : 46–52.[PubMed] [CrossRef]
70. Santin M,, Munoz L,, Rigau D . 2012. Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS One 7 : e32482. [PubMed] [CrossRef]
71. Aguado JM,, Torre-Cisneros J,, Fortun J,, Benito N,, Meije Y,, Doblas A,, Munoz P . 2009. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 48 : 1276–1284.[PubMed] [CrossRef]
72. Bumbacea D,, Arend SM,, Eyuboglu F,, Fishman JA,, Goletti D,, Ison MG,, Jones CE,, Kampmann B,, Kotton CN,, Lange C,, Ljungman P,, Milburn H,, Morris MI,, Muller E,, Munoz P,, Nellore A,, Rieder HL,, Sester U,, Theodoropoulos N,, Wagner D,, Sester M . 2012. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J 40 : 990–1013.[PubMed] [CrossRef]
73. Subramanian AK,, Morris MI . 2013. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Transplant 13(Suppl 4): 68–76.[PubMed] [CrossRef]
74. Horne DJ,, Narita M,, Spitters CL,, Parimi S,, Dodson S,, Limaye AP . 2013. Challenging issues in tuberculosis in solid organ transplantation. Clin Infect Dis 57 : 1473–1482.[PubMed] [CrossRef]
75. Kim SY,, Jung GS,, Kim SK,, Chang J,, Kim MS,, Kim YS,, Kang YA,, Joo DJ . 2013. Comparison of the tuberculin skin test and interferon-gamma release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection 41 : 103–110.[PubMed] [CrossRef]
76. Lange B,, Vavra M,, Kern WV,, Wagner D . 2012. Development of tuberculosis in immunocompromised patients with a positive tuberculosis-specific IGRA. Int J Tuberc Lung Dis 16 : 492–495.[PubMed] [CrossRef]
77. Theodoropoulos N,, Lanternier F,, Rassiwala J,, McNatt G,, Preczewski L,, DeMayo E,, Stosor V,, Ison MG . 2012. Use of the QuantiFERON-TB Gold interferon-gamma release assay for screening transplant candidates: a single-center retrospective study. Transpl Infect Dis 14 : 1–8.[PubMed] [CrossRef]
78. Casas S,, Munoz L,, Moure R,, Castellote J,, Guerra MR,, Gonzalez L,, Andreu A,, Rafecas AG,, Alcaide F,, Santin M . 2011. Comparison of the 2-step tuberculin skin test and the quantiFERON-TB Gold In-Tube Test for the screening of tuberculosis infection before liver transplantation. Liver Transpl 17 : 1205–1211.[PubMed] [CrossRef]
79. Wright PW,, Wallace RJ Jr,, Wright NW,, Brown BA,, Griffith DE . 1998. Sensitivity of fluorochrome microscopy for detection of Mycobacterium tuberculosis versus nontuberculous mycobacteria. J Clin Microbiol 36 : 1046–1049.[PubMed]
80. World Health Organization . 2011. Fluorescent Light-Emitting Diode (LED) microscopy for diagnosis of tuberculosis: policy statement. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/44602/1/9789241501613_eng.pdf
81. Pai M,, Daley P,, Hopewell PC . 2007. International standards for tuberculosis care: relevance and implications for laboratory professionals. Indian J Med Microbiol 25 : 89–92.
82. Dinnes J,, Deeks J,, Kunst H,, Gibson A,, Cummins E,, Waugh N,, Drobniewski F,, Lalvani A . 2007. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 11 : 1–196.[PubMed] [CrossRef]
83. Luo RF,, Banaei N . 2013. Molecular approaches and biomarkers for detection of Mycobacterium tuberculosis . Clin Lab Med 33 : 553–566.[PubMed] [CrossRef]
84. Pai M,, Kalantri S,, Dheda K . 2006. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn 6 : 423–432.[PubMed] [CrossRef]
85. Drobniewski F,, Nikolayevskyy V,, Maxeiner H,, Balabanova Y,, Casali N,, Kontsevaya I,, Ignatyeva O . 2013. Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation. BMC Med 11 : 190. [PubMed] [CrossRef]
86. Centers for Disease Control and Prevention (CDC) . 2013. Trends in tuberculosis—United States, 2012. MMWR Morb Mortal Wkly Rep 62 : 201–205.[PubMed]
87. Centers for Disease Control and Prevention (CDC) . 2009. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 58 : 7–10.[PubMed]
88. Bunsow E,, Ruiz-Serrano MJ,, Lopez Roa P,, Kestler M,, Viedma DG,, Bouza E . 2014. Evaluation of GeneXpert MTB/RIF for the detection of Mycobacterium tuberculosis and resistance to rifampin in clinical specimens. J Infect 68 : 338–343.[PubMed] [CrossRef]
89. Al-Ateah SM,, Al-Dowaidi MM,, El-Khizzi NA . 2012. Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Med J 33 : 1100–1105.[PubMed]
90. Piersimoni C,, Scarparo C . 2003. Relevance of commercial amplification methods for direct detection of Mycobacterium tuberculosis complex in clinical samples. J Clin Microbiol 41 : 5355–5365.[PubMed] [CrossRef]
91. Tortoli E,, Russo C,, Piersimoni C,, Mazzola E,, Dal Monte P,, Pascarella M,, Borroni E,, Mondo A,, Piana F,, Scarparo C,, Coltella L,, Lombardi G,, Cirillo DM . 2012. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 40 : 442–447.[PubMed] [CrossRef]
92. Vadwai V,, Boehme C,, Nabeta P,, Shetty A,, Alland D,, Rodrigues C . 2011. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol 49 : 2540–2545.[PubMed] [CrossRef]
93. Wilson D,, Mbhele L,, Badri M,, Morroni C,, Nachega J,, Chaisson RE,, Maartens G . 2011. Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. Int J Tuberc Lung Dis 15 : 919–924.[PubMed] [CrossRef]
94. Williamson DA,, Basu I,, Bower J,, Freeman JT,, Henderson G,, Roberts SA . 2012. An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis . Diagn Microbiol Infect Dis 74 : 207–209.[PubMed] [CrossRef]
95. Van Rie A,, Mellet K,, John MA,, Scott L,, Page-Shipp L,, Dansey H,, Victor T,, Warren R . 2012. False-positive rifampicin resistance on Xpert(R) MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 16 : 206–208.[PubMed] [CrossRef]
96. Lawn SD,, Mwaba P,, Bates M,, Piatek A,, Alexander H,, Marais BJ,, Cuevas LE,, McHugh TD,, Zijenah L,, Kapata N,, Abubakar I,, McNerney R,, Hoelscher M,, Memish ZA,, Migliori GB,, Kim P,, Maeurer M,, Schito M,, Zumla A . 2013. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 13 : 349–361.[PubMed] [CrossRef]
97. Steingart KR,, Schiller I,, Horne DJ,, Pai M,, Boehme CC,, Dendukuri N . 2014. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1 : CD009593. [PubMed] [CrossRef]
98. Christiansen DC,, Roberts GD,, Patel R . 2004. Mycobacterium celatum, an emerging pathogen and cause of false positive amplified Mycobacterium tuberculosis direct test. Diagn Microbiol Infect Dis 49 : 19–24.[PubMed] [CrossRef]
99. Simner PJ,, Hyle EP,, Buckwalter SP,, Branda JA,, Brown-Elliott BA,, Franklin J,, Toney NC,, de Man TJ,, Wallace RJ Jr,, Vasireddy R,, Gandhi RT,, Wengenack NL . 2014. Tenosynovitis caused by a novel nontuberculous Mycobacterium species initially misidentified as a member of the Mycobacterium tuberculosis complex. J Clin Microbiol 52 : 4414–4418.[PubMed] [CrossRef]
100. Tortoli E . 2003. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 16 : 319–354.[PubMed] [CrossRef]
101. Richter E,, Rusch-Gerdes S,, Hillemann D . 2006. Evaluation of the GenoType Mycobacterium Assay for identification of mycobacterial species from cultures. J Clin Microbiol 44 : 1769–1775.[PubMed] [CrossRef]
102. Tortoli E,, Mariottini A,, Mazzarelli G . 2003. Evaluation of INNO-LiPA MYCOBACTERIA v2: improved reverse hybridization multiple DNA probe assay for mycobacterial identification. J Clin Microbiol 41 : 4418–4420.[PubMed] [CrossRef]
103. Tortoli E,, Pecorari M,, Fabio G,, Messino M,, Fabio A . 2010. Commercial DNA probes for mycobacteria incorrectly identify a number of less frequently encountered species. J Clin Microbiol 48 : 307–310.[PubMed] [CrossRef]
104. Gitti Z,, Neonakis I,, Fanti G,, Kontos F,, Maraki S,, Tselentis Y . 2006. Use of the GenoType Mycobacterium CM and AS assays to analyze 76 nontuberculous mycobacterial isolates from Greece. J Clin Microbiol 44 : 2244–2246.[PubMed] [CrossRef]
105. Hofmann-Thiel S,, Turaev L,, Alnour T,, Drath L,, Mullerova M,, Hoffmann H . 2011. Multi-centre evaluation of the speed-oligo Mycobacteria assay for differentiation of Mycobacterium spp. in clinical isolates. BMC Infect Dis 11 : 353. [PubMed] [CrossRef]
106. Lara-Oya A,, Mendoza-Lopez P,, Rodriguez-Granger J,, Fernandez-Sanchez AM,, Bermudez-Ruiz MP,, Toro-Peinado I,, Palop-Borras B,, Navarro-Mari JM,, Martinez-Lirola MJ . 2013. Evaluation of the speed-oligo direct Mycobacterium tuberculosis assay for molecular detection of mycobacteria in clinical respiratory specimens. J Clin Microbiol 51 : 77–82.[PubMed] [CrossRef]
107. Makinen J,, Sarkola A,, Marjamaki M,, Viljanen MK,, Soini H . 2002. Evaluation of genotype and LiPA MYCOBACTERIA assays for identification of Finnish mycobacterial isolates. J Clin Microbiol 40 : 3478–3481.[PubMed] [CrossRef]
108. Russo C,, Tortoli E,, Menichella D . 2006. Evaluation of the new GenoType Mycobacterium assay for identification of mycobacterial species. J Clin Microbiol 44 : 334–339.[PubMed] [CrossRef]
109. Daley P,, Petrich A,, May K,, Luinstra K,, Rutherford C,, Chedore P,, Jamieson F,, Smieja M . 2008. Comparison of in-house and commercial 16S rRNA sequencing with high-performance liquid chromatography and genotype AS and CM for identification of nontuberculous mycobacteria. Diagn Microbiol Infect Dis 61 : 284–293.[PubMed] [CrossRef]
110. El Khechine A,, Couderc C,, Flaudrops C,, Raoult D,, Drancourt M . 2011. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of mycobacteria in routine clinical practice. PLoS One 6 : e24720. [PubMed] [CrossRef]
111. Saleeb PG,, Drake SK,, Murray PR,, Zelazny AM . 2011. Identification of mycobacteria in solid-culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 49 : 1790–1794.[PubMed] [CrossRef]
112. Mather CA,, Rivera SF,, Butler-Wu SM . 2014. Comparison of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry systems for identification of mycobacteria using simplified protein extraction protocols. J Clin Microbiol 52 : 130–138.[PubMed] [CrossRef]
113. McNabb SJ,, Braden CR,, Navin TR . 2002. DNA fingerprinting of Mycobacterium tuberculosis: lessons learned and implications for the future. Emerg Infect Dis 8 : 1314–1319.[PubMed] [CrossRef]
114. Driscoll JR . 2009. Spoligotyping for molecular epidemiology of the Mycobacterium tuberculosis complex. Methods Mol Biol 551 : 117–128.[PubMed] [CrossRef]
115. Sola C,, Filliol I,, Legrand E,, Lesjean S,, Locht C,, Supply P,, Rastogi N . 2003. Genotyping of the Mycobacterium tuberculosis complex using MIRUs: association with VNTR and spoligotyping for molecular epidemiology and evolutionary genetics. Infect Genet Evol 3 : 125–133.[PubMed] [CrossRef]
116. Crawford JT . 2003. Genotyping in contact investigations: a CDC perspective. Int J Tuberc Lung Dis 7 : S453–S457.[PubMed]
117. Niemann S,, Supply P . 2014. Diversity and evolution of Mycobacterium tuberculosis: moving to whole-genome-based approaches. Cold Spring Harb Perspect Med 4 : a021188. [PubMed] [CrossRef]
118. Kato-Maeda M,, Metcalfe JZ,, Flores L . 2011. Genotyping of Mycobacterium tuberculosis: application in epidemiologic studies. Future Microbiol 6 : 203–216.[PubMed] [CrossRef]
119. Tenover FC,, Crawford JT,, Huebner RE,, Geiter LJ,, Horsburgh CR Jr,, Good RC . 1993. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol 31 : 767–770.[PubMed]
120. Centers for Disease Control and Prevention (CDC) . 2015. Revised device labeling for the Cepheid Xpert MTB/RIF assay for detecting Mycobacterium tuberculosis . MMWR Morb Mortal Wkly Rep 64 : 193. [PubMed]
121. Lipsky BA,, Gates J,, Tenover FC,, Plorde JJ . 1984. Factors affecting the clinical value of microscopy for acid-fast bacilli. Rev Infect Dis 6 : 214–222.[PubMed] [CrossRef]
122. Bhattacharya M,, Dietrich S,, Mosher L,, Siddiqui F,, Reisberg BE,, Paul WS,, Warren JR . 1998. Cross-contamination of specimens with Mycobacterium tuberculosis: clinical significance, causes, and prevention. Am J Clin Pathol 109 : 324–330.[PubMed] [CrossRef]
123. Burman WJ,, Reves RR . 2000. Review of false-positive cultures for Mycobacterium tuberculosis and recommendations for avoiding unnecessary treatment. Clin Infect Dis 31 : 1390–1395.[PubMed] [CrossRef]
124. Agerton T,, Valway S,, Gore B,, Pozsik C,, Plikaytis B,, Woodley C,, Onorato I . 1997. Transmission of a highly drug-resistant strain (strain W1) of Mycobacterium tuberculosis. Community outbreak and nosocomial transmission via a contaminated bronchoscope. JAMA 278 : 1073–1077.[PubMed] [CrossRef]
125. Brown NM,, Hellyar EA,, Harvey JE,, Reeves DS . 1993. Mycobacterial contamination of fibreoptic bronchoscopes. Thorax 48 : 1283–1285.[PubMed] [CrossRef]
126. Gubler JG,, Salfinger M,, von Graevenitz A . 1992. Pseudoepidemic of nontuberculous mycobacteria due to a contaminated bronchoscope cleaning machine. Report of an outbreak and review of the literature. Chest 101 : 1245–1249.[PubMed] [CrossRef]
127. Segal-Maurer S,, Kreiswirth BN,, Burns JM,, Lavie S,, Lim M,, Urban C,, Rahal JJ Jr . 1998. Mycobacterium tuberculosis specimen contamination revisited: the role of laboratory environmental control in a pseudo-outbreak. Infect Control Hosp Epidemiol 19 : 101–105.[PubMed] [CrossRef]
128. Small PM,, McClenny NB,, Singh SP,, Schoolnik GK,, Tompkins LS,, Mickelsen PA . 1993. Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures. J Clin Microbiol 31 : 1677–1682.[PubMed]
129. Eckburg PB,, Buadu EO,, Stark P,, Sarinas PS,, Chitkara RK,, Kuschner WG . 2000. Clinical and chest radiographic findings among persons with sputum culture positive for Mycobacterium gordonae: a review of 19 cases. Chest 117 : 96–102.[PubMed] [CrossRef]
130. Weinberger M,, Berg SL,, Feuerstein IM,, Pizzo PA,, Witebsky FG . 1992. Disseminated infection with Mycobacterium gordonae: report of a case and critical review of the literature. Clin Infect Dis 14 : 1229–1239.[PubMed] [CrossRef]
131. Griffith DE,, Aksamit T,, Brown-Elliott BA,, Catanzaro A,, Daley C,, Gordin F,, Holland SM,, Horsburgh R,, Huitt G,, Iademarco MF,, Iseman M,, Olivier K,, Ruoss S,, von Reyn CF,, Wallace RJ Jr,, Winthrop K . 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 : 367–416.[PubMed] [CrossRef]
132. Clinical and Laboratory Standards Institute (CLSI) . 2011. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard-Second Edition; CLSI Document M24-A2. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA.
133. Campbell PJ,, Morlock GP,, Sikes RD,, Dalton TL,, Metchock B,, Starks AM,, Hooks DP,, Cowan LS,, Plikaytis BB,, Posey JE . 2011. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis . Antimicrob Agents Chemother 55 : 2032–2041.[PubMed] [CrossRef]
134. Almeida Da Silva PE,, Palomino JC . 2011. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 66 : 1417–1430.[PubMed] [CrossRef]
135. Rusch-Gerdes S,, Pfyffer GE,, Casal M,, Chadwick M,, Siddiqi S . 2006. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 44 : 688–692.[PubMed] [CrossRef]
136. Abuali MM,, Katariwala R,, LaBombardi VJ . 2012. A comparison of the Sensititre(R) MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis . Eur J Clin Microbiol Infect Dis 31 : 835–839.[PubMed] [CrossRef]
137. Hall L,, Jude KP,, Clark SL,, Dionne K,, Merson R,, Boyer A,, Parrish NM,, Wengenack NL . 2012. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents. J Clin Microbiol 50 : 3732–3734.[PubMed] [CrossRef]
138. Pandian TK,, Deziel PJ,, Otley CC,, Eid AJ,, Razonable RR . 2008. Mycobacterium marinum infections in transplant recipients: case report and review of the literature. Transpl Infect Dis 10 : 358–363.[PubMed] [CrossRef]
139. Longworth SA,, Blumberg EA,, Barton TD,, Vinnard C . 2015. Non-tuberculous mycobacterial infections after solid organ transplantation: a survival analysis. Clin Microbiol Infect 21 : 43–47.[PubMed] [CrossRef]
140. Henkle E,, Winthrop KL . 2015. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med 36 : 91–99.[PubMed] [CrossRef]
141. Candido PH,, Nunes Lde S,, Marques EA,, Folescu TW,, Coelho FS,, de Moura VC,, da Silva MG,, Gomes KM,, Lourenco MC,, Aguiar FS,, Chitolina F,, Armstrong DT,, Leao SC,, Neves FP,, Mello FC,, Duarte RS . 2014. Multidrug-resistant nontuberculous mycobacteria isolated from cystic fibrosis patients. J Clin Microbiol 52 : 2990–2997.[PubMed] [CrossRef]

Tables

Mycobacteria
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819040.chap16-1,webId=/content/author/10.1128/9781555819040.chap16-1,properties={foaf_givenname=Patricia J., foaf_name=Patricia J. Simner, foaf_surname=Simner, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819040.chap16-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819040.chap16-2,webId=/content/author/10.1128/9781555819040.chap16-2,properties={foaf_givenname=Gail L., foaf_name=Gail L. Woods, foaf_surname=Woods, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819040.chap16-aff2]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819040.chap16-3,webId=/content/author/10.1128/9781555819040.chap16-3,properties={foaf_givenname=Nancy L., foaf_name=Nancy L. Wengenack, foaf_surname=Wengenack, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819040.chap16-aff3]]}]]
Citation: Simner P, Woods G, Wengenack N. 2016. Mycobacteria, p 367-389. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0016-2015
/content/10.1128/9781555819040.chap16.tab16-1
Table 1

Phenotypic characteristics of selected mycobacteria

Generic image for table
Table 1

Phenotypic characteristics of selected mycobacteria

Citation: Simner P, Woods G, Wengenack N. 2016. Mycobacteria, p 367-389. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0016-2015
/content/10.1128/9781555819040.chap16.tab16-2
Table 2

Phenotypic groupings of mycobacteria

Generic image for table
Table 2

Phenotypic groupings of mycobacteria

Citation: Simner P, Woods G, Wengenack N. 2016. Mycobacteria, p 367-389. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0016-2015
/content/10.1128/9781555819040.chap16.tab16-3
Table 3

Comparison of conventional and newer mycobacterial test methods

Generic image for table
Table 3

Comparison of conventional and newer mycobacterial test methods

Citation: Simner P, Woods G, Wengenack N. 2016. Mycobacteria, p 367-389. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0016-2015
/content/10.1128/9781555819040.chap16.tab16-4
Table 4

Suggested turnaround times for mycobacteriology laboratory tests

Generic image for table
Table 4

Suggested turnaround times for mycobacteriology laboratory tests

Citation: Simner P, Woods G, Wengenack N. 2016. Mycobacteria, p 367-389. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0016-2015
/content/10.1128/9781555819040.chap16.tab16-5
Table 5

Primary and secondary drugs for susceptibility testing of mycobacteria

Generic image for table
Table 5

Primary and secondary drugs for susceptibility testing of mycobacteria

Citation: Simner P, Woods G, Wengenack N. 2016. Mycobacteria, p 367-389. In Hayden R, Wolk D, Carroll K, Tang Y (ed),

Diagnostic Microbiology of the Immunocompromised Host, Second Edition

. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.DMIH2-0016-2015

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error